Key result
Oxidized low-density lipoprotein lessens the anti-coagulant function of tissue-factor-pathway inhibitor through oxidative modification and accelerated degradation in cultured human endothelial cells.
Why the study?
Does oxidized low-density lipoprotein impair the anti-coagulant function of tissue-factor-pathway inhibitor in cultured human endothelial cells?
Does oxidized low-density lipoprotein impair the anti-coagulant function of tissue-factor-pathway inhibitor in cultured human endothelial cells?
Oxidized LDL impairs the anti-coagulant function of TFPI through oxidative modification and accelerated degradation in human endothelial cells, providing a potential mechanism for the pro-thrombotic state associated with atherosclerosis.
Answers are grounded in this paper and cite their sources.
May promote endothelial pro-thrombotic state in atherosclerosis; leaves open in vivo relevance and therapeutic targeting of TFPI.
We have examined whether oxidized low-density lipoprotein (ox-LDL) affects the function of tissue-factor-pathway inhibitor (TFPI), an anti-coagulant regulator in the extrinsic pathway of coagulation, in cultured human umbilical vein endothelial cells (HUVEC). Treatment of culture medium of HUVEC with ox-LDL, but not with native or acetylated LDLs, drastically decreased the reactivity of TFPI to its antibody specific for Kunitz domain 1 or one specific for the conformation between Kunitz 1 and 2 of TFPI, and caused a rapid, concentration-dependent decrease in the functional activity of TFPI to inhibit Factor X activation. When 5ng of recombinant TFPI (rTFPI) was mixed with 10µg of ox-LDL for 30min, almost all of the rTFPI was detected in the ox-LDL fraction and no free rTFPI was observed on non-denaturing PAGE, in contrast with the virtual absence of rTFPI in the native LDL fraction. Ox-LDL decreased the antigen level of TFPI in the lysate of HUVEC in a time-dependent manner. It did not affect the mRNA level, but ox-LDL-dependent reduction of the TFPI antigen level in HUVEC was reversed by the simultaneous treatment of ox-LDL with bafilomycin A1, an inhibitor of the lysosomal proton pump. These results indicate that ox-LDL lessens the anti-coagulant function of TFPI through both oxidative modification and accelerated degradation of the molecule outside and inside HUVEC respectively.
No takes yet. Share an insight, caveat, or question.
Horie et al. (2000) studied this question. Oxidized low-density lipoprotein (ox-LDL) vs. Native or acetylated LDLs was evaluated on Reactivity and functional activity of TFPI. Oxidized low-density lipoprotein lessens the anti-coagulant function of tissue-factor-pathway inhibitor through oxidative modification and accelerated degradation in cultured human endothelial cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: